Format

Send to

Choose Destination
Invest New Drugs. 2001;19(1):77-80.

A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix--a Gynecologic Oncology Group Study.

Author information

1
Gynecologic Oncology, University of California, San Diego, USA.

Abstract

PURPOSE:

The Gynecologic Oncology Group performed a Phase II study to determine the response rate of Pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix.

METHODS:

PZA was administered at a dose of 750 mg/m2 intravenously over three hours every three weeks.

RESULTS:

Among 21 evaluable patients, there were no complete and one (4.2%) partial response. The major toxicities were hematologic.

CONCLUSION:

PZA at the dose and schedule employed has insignificant activity in this population.

PMID:
11291835
DOI:
10.1023/a:1006469006460
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center